Centessa Pharmaceuticals (CNTA) Net Cash Flow (2022 - 2026)

Centessa Pharmaceuticals has reported Net Cash Flow over the past 4 years, most recently at $9.5 million for Q4 2025.

  • Quarterly Net Cash Flow rose 163.75% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$320.8 million through Dec 2025, down 226.32% year-over-year, with the annual reading at -$320.8 million for FY2025, 226.32% down from the prior year.
  • Net Cash Flow was $9.5 million for Q4 2025 at Centessa Pharmaceuticals, up from $7.1 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $269.6 million in Q3 2024 and troughed at -$276.5 million in Q1 2025.
  • The 4-year median for Net Cash Flow is -$40.9 million (2022), against an average of -$33.4 million.
  • Year-over-year, Net Cash Flow soared 934.45% in 2024 and then plummeted 2656.93% in 2025.
  • A 4-year view of Net Cash Flow shows it stood at -$51.9 million in 2022, then rose by 17.25% to -$43.0 million in 2023, then skyrocketed by 65.47% to -$14.8 million in 2024, then skyrocketed by 163.75% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Net Cash Flow are $9.5 million (Q4 2025), $7.1 million (Q3 2025), and -$60.8 million (Q2 2025).